AI Labs

Insitro

Medium1/3 relationships sourcedProfile verified Aug 14, 2026
OverviewSourcesM&A fitRelationship mapStoryMilestones

30-Second Executive Brief

Executive Assessment

Insitro functions as a regional institution within AI Labs, backed by 47% sourcing coverage, with a stable competitive position.

  • Maintains 3 mapped relationships across the graph
  • 47% sourcing coverage across sourced relationships
  • Tracked as regional institution within the AI Labs category

Executive Snapshot

Strategic Role
Regional Institution
Sourcing Coverage
47%
View Methodology →

Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.

Ecosystem Influence
Moderate
Strategic Momentum
Insufficient Data

Coverage

Mapped Relationships
3
Technology Domains
4

Strategic Implications

  • Central node connecting multiple strategic ecosystems
  • Directly influences technology and capital flows
  • Material relevance to downstream dependency mapping

Top Opportunities

TherML platform expected to broaden insitro's addressable modality range beyond its original small-molecule and genomics focusContinued expansion of pharma partnerships (Lilly, Bristol-Myers) expected to fund pipeline advancement toward the clinic

Top Risks

Pharma partnership revenue is non-dilutive but ties a portion of near-term economics to partner-controlled program decisionsModality-agnostic platform strategy requires continued execution across several distinct drug modalities simultaneously

Critical Dependencies

Continue to Dependency Graph ↓

A machine-learning-driven drug discovery company that has raised approximately $800 million in capital (including $150 million from non-dilutive pharma partnerships), and expanded its Eli Lilly collaboration in September 2025 to build ML models predicting small-molecule pharmacological properties. Insitro acquired CombinAbleAI in January 2026 and launched its TherML (Therapeutic Machine Learning) platform, completing a full-stack, modality-agnostic capability spanning small molecules, oligonucleotides, antibodies, and other complex biologics.

⚡

Sources

Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.

Evidence

2 sources

⚡

Acquisition & Investment Fit

AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.

⚡

Relationship Map

The relationships surrounding Insitro — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.

2 levels3 levels 🔒5 levels 🔒

Connection type

Sign in free to click a node and explore →

Click any node to make it the new center. Scroll to zoom, drag to pan.

⚡

The Story So Far

Jan 2018: Founded→Sep 2025: insitro expands Lilly collaboration to build ML models predicting small-molecule pharmaco…→Jan 2026: Acquires CombinAbleAI, launches TherML platform→Jan 2026: insitro acquires CombinAbleAI, launches TherML full-stack drug design platform→Aug 2026: Expanding into a modality-agnostic full-stack platform trades focus for addressable bread… (unconfirmed)

Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.

Market Intelligence

Unverified

Credibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.

Expanding into a modality-agnostic full-stack platform trades focus for addressable breadth

22% confidence

Insitro raised approximately $800 million in total capital, including $150 million from non-dilutive pharma partnerships, and launched its TherML platform in January 2026 to span small molecules, oligonucleotides, antibodies, and other complex biologics after acquiring CombinAbleAI.

This is InsightNodes' own interpretive read: Insitro's acquisition of CombinAbleAI and TherML launch broadened its capability across small molecules, oligonucleotides, antibodies and other biologics, but doing so on roughly $800 million in total capital (including partner-tied, non-dilutive funding) means the company is now executing across more drug modalities simultaneously with a moderate capital base relative to more narrowly focused or better-funded peers.

insitro corporate site · Aug 14, 2026

Isomorphic LabsXaira Therapeutics
⚡

Insitro's Timeline

A sourced, dated history of Insitro's key moments — founding to present.

  1. Jan 2018 · Founded

    Insitro was founded to apply machine learning to drug discovery and development.

  2. Jan 2026 · Acquires CombinAbleAI, launches TherML platform

    Insitro acquired CombinAbleAI and launched its TherML (Therapeutic Machine Learning) platform, completing a full-stack, modality-agnostic drug discovery and design capability spanning small molecules, oligonucleotides, antibodies, and other complex biologics.